AUGX: Augmedix, Inc. Stock

by  •  • Comments Off on AUGX: Augmedix, Inc. Stock

SIC 7389 – Business Services, Not Elsewhere Classified

Valuation
Market Cap ($M) 123.31
Enterprise Value ($M) 97.40
Book Value ($M) 23.32
Book Value / Share 0.48
Price / Book 5.29
NCAV ($M) 13.43
NCAV / Share 0.28
Price / NCAV 9.18

Profitability (mra)
Return on Invested Capital (ROIC) -0.39
Return on Assets (ROA) -0.58
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 2.41
Current Ratio 2.41

Balance Sheet (mrq) ($M)
Current Assets 56.82
Assets 66.71
Liabilities 43.39
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 44.85
Operating Income -18.78
Net Income -19.17
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -15.40
Cash from Investing -3.15
Cash from Financing 43.37

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-26 13D/A Dcm Vi, L.p. 0.60 -91.90
02-09 13G Samjo Management, LLC 6.10
11-22 13D/A Redmile Group, LLC 40.70 9.12

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO
2024-03-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-02 34,319 356,552 9.63
2024-05-01 71,123 855,880 8.31
2024-04-30 21,601 83,127 25.99
2024-04-29 34,131 79,546 42.91

(click for more detail)

Similar Companies
ALLR – Allarity Therapeutics, Inc. BAOS – Baosheng Media Group Holdings Limited
CREG – Smart Powerr Corp.


Financial data and stock pages provided by
Fintel.io